A medical expert discusses tailoring treatment strategies for standard-risk and high-risk multiple myeloma patients, considering patient characteristics and transplant eligibility when selecting treatment combinations.
Cilta-cel Yields Sustained Responses in R/R Multiple Myeloma
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Cranial Nerve Palsy Present Across CARTITUDE Trials in Multiple Myeloma
Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.
Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Linvoseltamab Shows Responses, Safety in Relapsed/Refractory Myeloma
Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.